Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 13, 2026.

Emphasis Of MatterExceptional ItemPat NegativeResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.9%Reaction day

₹458.90

prior close

₹463.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.7%+4.7% vs market

Pharmaceuticals peers, median of 154sector-0.5%+4.5% vs sector

On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.6

10m

+3.7

15m

+3.8

30m

+4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.9-0.7+4.7-0.5+4.5

Next day

+6.8+0.2+6.6-0.0+6.8

+6.4+0.5+5.9+0.0+6.4

+5.5-0.9+6.4-0.9+6.4

+4.5-1.0+5.5-1.5+5.9

+3.3-0.9+4.2-1.2+4.4

+4.4-2.0+6.4-2.1+6.5

15d

+9.6-6.9+16.5-5.0+14.6

+0.7-10.5+11.2-7.4+8.1

+19.6+1.5+18.0-0.3+19.9

+12.0+3.8+8.2+2.5+9.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs and Pharmaceuticals' board approved Q3 FY26 results on February 13, 2026. Consolidated revenue from operations grew to ₹11,595.87 million, up about 14.8% YoY from ₹10,104.11 million, while consolidated PAT for the quarter was ₹676.74 million vs ₹663.12 million. On a standalone basis, Q3 revenue rose modestly to ₹3,686.06 million (₹3,373.07 million YoY), but standalone PAT fell sharply to ₹281.14 million from ₹411.68 million, hit by an exceptional charge of ₹38.08 million related to the new Labour Codes. For nine months FY26, consolidated revenue stood at ₹32,001.49 million and consolidated PAT was ₹1,750.55 million (down from ₹1,941.71 million YoY). The auditor's limited review report is unqualified but includes an emphasis-of-matter paragraph on the ongoing Income Tax search and seizure matter from January 2025, whose financial impact remains unascertainable. The CDMO segment continues to dominate, contributing roughly 79% of consolidated external revenue in Q3.

Likely market impact

Mixed picture for shareholders – top-line growth on a consolidated basis is healthy, especially in CDMO, but standalone profitability has been compressed by the Labour Codes exceptional item and the still-unresolved Income Tax investigation remains an overhang. The unqualified review with an emphasis-of-matter suggests no immediate accounting concern, but investors should watch for further developments on the tax proceedings and any margin pressure in the API and Trade Generics segments, which reported losses.